| 查看: 1067 | 回复: 1 | |||
| 当前主题已经存档。 | |||
huajieyu464木虫 (正式写手)
|
[交流]
新的治疗膝关节炎药物
|
||
|
Naproxcinod (formely HCT 3012) Inflammation in osteoarthritis - phase 3 Naproxcinod is NicOx’ lead product, in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. It is a unique nitric oxide-donating anti-inflammatory and the first of the CINOD class (COX-Inhibiting Nitric Oxide Donators). NicOx aims to develop naproxcinod as a powerful anti-inflammatory agent with no detrimental effects on blood pressure and good gastrointestinal tolerability and safety. Top-line results from the first phase 3 study were successful. This represents an important step towards NicOx’ goal of making naproxcinod the drug-of-choice for osteoarthritis patients. |
回复此楼» 猜你喜欢
哪里做甘氨酸受体与配体结合率的试验
已经有0人回复
-
脑梗怎么治疗
已经有3人回复
-
药物学论文润色/翻译怎么收费?
已经有203人回复
-
脑梗怎么治疗
已经有0人回复
-
生物组织中有目标分析物，专属性怎么做
已经有0人回复
-
关于SCI杂志发表挂名
已经有32人回复
-
医药研发数据库资源
已经有4人回复
-
药物检测中微生物限度计数结果判断
已经有0人回复
-
申博自荐
已经有2人回复
-
请教执业药师报考的一些问题
已经有4人回复
100